PUBLISHER: Grand View Research | PRODUCT CODE: 1405902
PUBLISHER: Grand View Research | PRODUCT CODE: 1405902
The global antisense & RNAi therapeutics market size is expected to reach USD 14.66 billion by 2030, registering a CAGR of 18.12% from 2024 to 2030, according to a new report by Grand View Research, Inc. Developments in biological vectors & nanotechnology and increased financial help for clinical investigations, including the launch of novel drug molecules, are critical in product development and are driving market expansion.
Multinational healthcare organizations raise awareness and assist in the development of novel remedies for a variety of ailments. Private institutes and companies participating in conducting trials through supporting research institutes are predicted to considerably fuel sector expansion. For instance, in March 2022, Biogen Inc. and Ionis Pharmaceuticals, Inc. announced outcomes from the Phase 1 study of an investigational antisense oligonucleotide for treating people with amyotrophic lateral sclerosis (ALS). Such increasing clinical trials through industry participants is anticipated to propel the market growth by rising the product launches based on antisense and RNAi therapies.
Antisense and RNAi therapies can be used to treat various disorders that impact the cell growth cycle and target nucleic acids. The ability of miRNA to regenerate gene expression and regulate protein production, consequently impacting industrial advancement, is receiving much attention. According to the article published by the American Association for the Advancement of Science in July 2023, an antisense therapy developed by UMass Chan Medical School and RUSH University Medical Center is found useful in restoring production of the protein FMRP in cell specimens taken from individuals suffering from fragile X syndrome. Such advancements in the industry are expected to propel the demand for RNAi and antisense therapeutics for treating numerous diseases over the forecast period.